Akari Therapeutics Plc Sponsored ADR Aktie News

Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and a novel antibody construct to address one of oncology's most challenging and valuable solid tumor targets, CEACAM5 TAMPA and LONDON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotec...

Access the Akari CEO Corner  here

In-person presentation on Tuesday, January 13 th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari's ADC platform, strategic priorities and key milestones for 2026 TAMPA, Fla.

TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today issued the following letter to shareholders from its President and Chief Executive Officer, Abizer Gaslightwala.

Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling Work Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling Work

Watch the “What This Means” video here

New cash portion of offering includes >20% participation from Directors, Officers and Executive Management New cash portion of offering includes >20% participation from Directors, Officers and Executive Management

Data highlights the ability of Akari's Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates